ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2023 · 122 positions · Total reported value $4.55B · Top-10 concentration 34.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2023 13F filing, ORBIMED ADVISORS LLC disclosed 122 equity positions with a combined reported value of $4.55B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M). By sector, the heaviest allocations are Health Care 69.1%, Consumer Discretionary 1.8%.

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions.

The largest new positions opened in Q3 2023 were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • SVA Sinovac Biotech Ltd. · $340.00M
  • BSX BOSTON SCIENTIFIC CORP · $174.60M
  • HUM HUMANA INC COM · $166.63M
  • ISRG INTUITIVE SURGICAL INC · $145.85M
  • BIIB BIOGEN INC · $143.10M
  • BMRN BIOMARIN PHARMACEUTICAL INC COM · $142.91M
  • ELVN ENLIVEN THERAPEUTICS INC COM · $122.92M
  • MRK MERCK & CO INC · $108.61M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 69.1%
Technology 0.2%
Materials 0.0%
Other 27.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.72M $340.00M 7.48%
7.48%
New
2 3.31M $174.60M 3.84%
3.84%
New
3 342.50K $166.63M 3.67%
3.67%
New
4 499.00K $145.85M 3.21%
3.21%
New
5 556.80K $143.10M 3.15%
3.15%
New
6 1.62M $142.91M 3.14%
3.14%
New
7 9.00M $122.92M 2.70%
2.70%
New
8 1.05M $108.61M 2.39%
2.39%
New
9 2.27M $106.63M 2.35%
2.35%
New
10 186.00K $99.91M 2.20%
2.20%
New
11 2.17M $98.41M 2.17%
2.17%
New
12 3.97M $91.75M 2.02%
2.02%
New
13 401.90K $90.78M 2.00%
2.00%
New
14 2.90M $86.13M 1.90%
1.90%
New
15 2.24M $84.53M 1.86%
1.86%
New
16 14.57M $83.47M 1.84%
1.84%
New
17 1.22M $80.68M 1.77%
1.77%
New
18 73.11M $80.43M 1.77%
1.77%
New
19 2.90M $78.85M 1.74%
1.74%
New
20 269.00K $73.51M 1.62%
1.62%
New
21 143.80K $72.79M 1.60%
1.60%
New
22 17.99M $67.39M 1.48%
1.48%
New
23 231.50K $66.23M 1.46%
1.46%
New
24 529.20K $64.15M 1.41%
1.41%
New
25 3.78M $61.58M 1.35%
1.35%
New
26 2.62M $58.23M 1.28%
1.28%
New
27 165.40K $57.52M 1.26%
1.26%
New
28 5.33M $54.17M 1.19%
1.19%
New
29 3.44M $51.86M 1.14%
1.14%
New
30 1.01M $51.34M 1.13%
1.13%
New
31 330.00K $49.19M 1.08%
1.08%
New
32 2.29M $48.69M 1.07%
1.07%
New
33 1.51M $48.29M 1.06%
1.06%
New
34 17.71M $47.65M 1.05%
1.05%
New
35 415.90K $46.79M 1.03%
1.03%
New
36 4.08M $46.73M 1.03%
1.03%
New
37 12.05M $45.13M 0.99%
0.99%
New
38 22.36M $44.05M 0.97%
0.97%
New
39 920.58K $40.74M 0.90%
0.90%
New
40 6.56M $40.30M 0.89%
0.89%
New
41 3.32M $40.14M 0.88%
0.88%
New
42 5.56M $39.58M 0.87%
0.87%
New
43 4.01M $39.04M 0.86%
0.86%
New
44 7.62M $38.32M 0.84%
0.84%
New
45 253.31K $36.99M 0.81%
0.81%
New
46 5.78M $36.93M 0.81%
0.81%
New
47 70.00K $35.29M 0.78%
0.78%
New
48 9.24M $34.93M 0.77%
0.77%
New
49 127.30K $34.21M 0.75%
0.75%
New
50 10.91M $33.71M 0.74%
0.74%
New

FAQ

What did ORBIMED ADVISORS LLC buy in 2023-Q3?

In its 2023-Q3 13F filing, ORBIMED ADVISORS LLC reported 122 equity positions worth $4.55B in aggregate; its largest disclosed positions were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.55B of long equity holdings across 122 positions as of 2023-Q3. Top-10 holdings account for 34.1% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →